Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of TQD3606 in Healthy Subjects
NCT05340530Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQD3606 in bacterial infection (5 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Concentration and Area under the plasma concentration-time curve from initial dosing to 24 hours. Status: unknown.
02
Drugs
TQD3606
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05340530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340530.